Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Kengo Akashi"'
Autor:
Yuzuru Yamamoto, Takaichi Okano, Hirotaka Yamada, Kengo Akashi, Sho Sendo, Yo Ueda, Akio Morinobu, Jun Saegusa
Publikováno v:
Arthritis Research & Therapy, Vol 23, Iss 1, Pp 1-10 (2021)
Abstract Background Systemic sclerosis (SSc) is a chronic autoimmune-mediated connective tissue disorder. Although the etiology of the disease remains undetermined, SSc is characterized by fibrosis and proliferative vascular lesions of the skin and i
Externí odkaz:
https://doaj.org/article/62301b154fe244268a832ff99e4400db
Autor:
Yusuke Murai, Takuji Kurimoto, Sotaro Mori, Kaori Ueda, Mari Sakamoto, Kengo Akashi, Yuko Yamada-Nakanishi, Makoto Nakamura
Publikováno v:
Case Reports in Ophthalmology, Vol 12, Iss 1, Pp 32-40 (2021)
We report a rare case of granulomatosis with polyangiitis (GPA) presenting with bilateral orbital apex syndrome (OAS). A 73-year-old woman with a history of endoscopic sinus surgery for ethmoidal sinusitis experienced a sudden decrease in visual acui
Externí odkaz:
https://doaj.org/article/e960402a109244a28eab193de2951816
Autor:
Kosuke Ebina, Toru Hirano, Yuichi Maeda, Wataru Yamamoto, Motomu Hashimoto, Koichi Murata, Tohru Takeuchi, Hideyuki Shiba, Yonsu Son, Hideki Amuro, Akira Onishi, Kengo Akashi, Ryota Hara, Masaki Katayama, Keiichi Yamamoto, Atsushi Kumanogoh, Makoto Hirao
Publikováno v:
Arthritis Research & Therapy, Vol 22, Iss 1, Pp 1-11 (2020)
Abstract Background This multi-center, retrospective study aimed to clarify retention rates and reasons for discontinuation of 7 biological disease-modifying antirheumatic drugs (bDMARDs) and tofacitinib (TOF), one of the janus kinase inhibitors, in
Externí odkaz:
https://doaj.org/article/4669e0ad46c94ef0981d1d8a12dd9861
Autor:
Motomu Hashimoto, Moritoshi Furu, Wararu Yamamoto, Takanori Fujimura, Ryota Hara, Masaki Katayama, Akira Ohnishi, Kengo Akashi, Shuzo Yoshida, Koji Nagai, Yonsu Son, Hideki Amuro, Toru Hirano, Kosuke Ebina, Ryuji Uozumi, Hiromu Ito, Masao Tanaka, Koichiro Ohmura, Takao Fujii, Tsuneyo Mimori
Publikováno v:
Arthritis Research & Therapy, Vol 20, Iss 1, Pp 1-10 (2018)
Abstract Background Clinical remission can be maintained after the discontinuation of biological disease-modifying antirheumatic drugs (bDMARDs) in some patients with rheumatoid arthritis (RA) (bDMARD-free remission (BFR)). It is unknown which bDMARD
Externí odkaz:
https://doaj.org/article/4cd5e2f3433e4dbcad326af2ee7761ea
Autor:
Soshi Takahashi, Jun Saegusa, Sho Sendo, Takaichi Okano, Kengo Akashi, Yasuhiro Irino, Akio Morinobu
Publikováno v:
Arthritis Research & Therapy, Vol 19, Iss 1, Pp 1-10 (2017)
Abstract Background The recent findings of cancer-specific metabolic changes, including increased glucose and glutamine consumption, have provided new therapeutic targets for consideration. Fibroblast-like synoviocytes (FLS) from rheumatoid arthritis
Externí odkaz:
https://doaj.org/article/7595bc5ee28c4ad1936221cc563f70ae
Autor:
Kosuke Ebina, Motomu Hashimoto, Wataru Yamamoto, Akira Ohnishi, Daijiro Kabata, Toru Hirano, Ryota Hara, Masaki Katayama, Shuzo Yoshida, Koji Nagai, Yonsu Son, Hideki Amuro, Kengo Akashi, Takanori Fujimura, Makoto Hirao, Keiichi Yamamoto, Ayumi Shintani, Atsushi Kumanogoh, Hideki Yoshikawa
Publikováno v:
PLoS ONE, Vol 13, Iss 3, p e0194130 (2018)
The purpose of this study was to evaluate the retention and discontinuation reasons of seven biological disease-modifying antirheumatic drugs (bDMARDs) in a real-world setting of patients with rheumatoid arthritis (RA). 1,037 treatment courses with b
Externí odkaz:
https://doaj.org/article/da74f67791e94618b8e588c6dd945d6e
Autor:
Shoko FUKUMITSU, Eriko SHINKAWA, Ken WASHIO, Kengo AKASHI, Takaichi OKANO, Sho SENDO, Akio MORINOBU, Ryusuke ONO, Hiroshi NAGAI, Chikako NISHIGORI
Publikováno v:
Nishi Nihon Hifuka. 84:121-125
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e8c479f520276ea06721134cdebd925f
https://doi.org/10.2336/nishinihonhifu.84.121
https://doi.org/10.2336/nishinihonhifu.84.121
Autor:
Yoichi Nakayama, Ryu Watanabe, Kosaku Murakami, Koichi Murata, Masao Tanaka, Hiromu Ito, Wataru Yamamoto, Kosuke Ebina, Kenichiro Hata, Yuri Hiramatsu, Masaki Katayama, Yonsu Son, Hideki Amuro, Kengo Akashi, Akira Onishi, Ryota Hara, Keiichi Yamamoto, Koichiro Ohmura, Shuichi Matsuda, Akio Morinobu, Motomu Hashimoto
Publikováno v:
Rheumatology International. 42:1227-1234
Rheumatoid factor (RF) binds to the fragment crystallizable (Fc) portion of immunoglobulin. It could bind to the Fc portion of anti-TNF inhibitors (TNFi) and attenuate the clinical efficacy. We tried to determine whether the therapeutic efficacy of T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2044894575eb18d59912b97e68d2f826
https://doi.org/10.1007/s00296-021-05086-w
https://doi.org/10.1007/s00296-021-05086-w
Autor:
Hidehiko Makino, Takuya Kotani, Kenichiro Hata, Daisuke Nishioka, Wataru Yamamoto, Ayaka Yoshikawa, Yumiko Wada, Yuri Hiramatsu, Hideyuki Shiba, Koji Nagai, Masaki Katayama, Yonsu Son, Hideki Amuro, Akira Onishi, Kengo Akashi, Ryota Hara, Toru Hirano, Motomu Hashimoto, Tohru Takeuchi
Publikováno v:
Modern Rheumatology.
The aim of this multi-centre retrospective study was to clarify the prognostic factors for respiratory-related death in patients with interstitial lung disease (ILD) complicated rheumatoid arthritis (RA). Patient background data, treatment regimen, a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e8978ea0adf29272d8e3ad07e35ab04
https://doi.org/10.1093/mr/roac115
https://doi.org/10.1093/mr/roac115
Autor:
Koichi Murata, Ryuji Uozumi, Motomu Hashimoto, Kosuke Ebina, Kengo Akashi, Akira Onishi, Koji Nagai, Ayaka Yoshikawa, Masaki Katayama, Yonsu Son, Hideki Amuro, Ryota Hara, Wataru Yamamoto, Ryu Watanabe, Kosaku Murakami, Masao Tanaka, Hiromu Ito, Akio Morinobu, Shuichi Matsuda
Publikováno v:
Modern Rheumatology. 32:834-838
Objectives Rheumatoid arthritis (RA) is a chronic inflammatory disease characterized by localized and generalized bone loss. The risk of fractures is doubled in patients with RA. Denosumab, an anti-RANKL monoclonal antibody, is used for those with os
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ad945228ee61719ec4e6ebfb53d12be
https://doi.org/10.1093/mr/roab043
https://doi.org/10.1093/mr/roab043